U.S. Markets close in 3 hrs 9 mins

Mark A. Emalfarb, Founder, Chairman, President and CEO of Dyadic International (DYAI), Interviews with The Wall Street Transcript

67 WALL STREET, New York - April 26, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation

Companies include: Dyadic International (DYAI) and many more.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, the Founder, Chairman, President and CEO of Dyadic International (DYAI) discusses company strategy and the outlook for this vital industry:

TWST: Please begin with a short introduction to Dyadic International.

Mr. Emalfarb: Dyadic International is a biotechnology company that operates around the globe, that has developed a technology platform that turns DNA or genes into proteins and enzymes in large scale affordably. We are using that technology to produce enzymes for converting biomass into cellulosic sugars to produce second-generation fuels and chemicals, like ethanol, butanol, succinic acid, lactic acid, etc.

We are also using that same technology to develop enzymes for animal feed and food, pulp and paper, textiles, etc., in the industrial enzyme business. We do that in several ways. We do it by producing our own products, selling them all over the globe in 35 countries, but we also do that by licensing technology to some of the world's biggest, best companies in their respective fields, where we actually bring the development and manufacturing capabilities of turning their discoveries into proteins and enzymes in large volumes affordably.

TWST: Would you give us more background on what the science is behind the C1 fungus technology platform?

Mr. Emalfarb: C1 technology platform is a fungus we found in Russia in the early 1990s. What we found and what we have today is like night and day. We spent over 20 years developing this technology to make this more robust, more versatile and more productive, so that it can turn more genes into more products more quickly, more affordably.

And what we've created there is a way to take the world's gene pool, whether it be from bacteria, yeast, fungi, humans, mollusks - I mean, any kind of living cell has its own genome, we can strip the genes from those genomes out, determine what the proteins and enzymes are, what markets and applications those may be for, and then insert those genes into our patented...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.